<SEC-DOCUMENT>0001564590-22-021266.txt : 20220525
<SEC-HEADER>0001564590-22-021266.hdr.sgml : 20220525
<ACCEPTANCE-DATETIME>20220525160618
ACCESSION NUMBER:		0001564590-22-021266
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20220524
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220525
DATE AS OF CHANGE:		20220525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50865
		FILM NUMBER:		22962927

	BUSINESS ADDRESS:	
		STREET 1:		1 CASPER STREET
		CITY:			DANBURY
		STATE:			CT
		ZIP:			06810
		BUSINESS PHONE:		818-661-5000

	MAIL ADDRESS:	
		STREET 1:		1 CASPER STREET
		CITY:			DANBURY
		STATE:			CT
		ZIP:			06810
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mnkd-8k_20220524.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-25T19:35:53.3447428+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cef399ca9569475da797e99c2658f7d2 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mnkd="http://www.mannkindcorp.com/20220524" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
mnkd-8k_20220524.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000000" name="dei:EntityRegistrantName" contextRef="C_0000899460_20220524_20220524">MANNKIND CORP</ix:nonNumeric>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000899460_20220524_20220524">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000002" name="dei:EntityCentralIndexKey" contextRef="C_0000899460_20220524_20220524">0000899460</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="mnkd-20220524.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000899460_20220524_20220524">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000899460</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-05-24</xbrli:startDate>
					<xbrli:endDate>2022-05-24</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="margin-bottom:0pt;border-top:Solid 2.5pt #000000;padding-top:0pt;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br />Washington, D.C. 20549<span style="font-weight:normal;"><br />_____________________</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000003" name="dei:DocumentType" contextRef="C_0000899460_20220524_20220524">8-K</ix:nonNumeric><span style="font-weight:normal;"><br />_____________________</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event Reported):&#160;&#160;<ix:nonNumeric id="F_000004" name="dei:DocumentPeriodEndDate" contextRef="C_0000899460_20220524_20220524" format="ixt:datemonthdayyearen">May 24, 2022</ix:nonNumeric> &#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MannKind Corporation<span style="font-size:10pt;font-weight:normal;"><br />(Exact Name of Registrant as Specified in Charter)</span></p>
<p style="margin-bottom:0pt;line-height:11pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top" style="width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000899460_20220524_20220524">000-50865</ix:nonNumeric></p></td>
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000899460_20220524_20220524">13-3607736</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction of Incorporation)</p></td>
<td valign="top" style="width:20%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="top" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification Number)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityAddressAddressLine1" contextRef="C_0000899460_20220524_20220524">1 Casper Street</ix:nonNumeric>, <ix:nonNumeric id="F_000009" name="dei:EntityAddressCityOrTown" contextRef="C_0000899460_20220524_20220524">Danbury</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressStateOrProvince" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:stateprovnameen">Connecticut</ix:nonNumeric> <ix:nonNumeric id="F_000011" name="dei:EntityAddressPostalZipCode" contextRef="C_0000899460_20220524_20220524">06810</ix:nonNumeric><span style="font-weight:normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices) (Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:CityAreaCode" contextRef="C_0000899460_20220524_20220524">(818)</ix:nonNumeric> <ix:nonNumeric id="F_000013" name="dei:LocalPhoneNumber" contextRef="C_0000899460_20220524_20220524">661-5000</ix:nonNumeric><span style="font-weight:normal;"><br />(Registrant's telephone number, including area code)</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A<span style="font-weight:normal;"><br />(Former name or former address, if changed since last report)</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="3" valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.35%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K):</p></td>
</tr>
<tr>
<td valign="top" style="width:2.9%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.38%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:WrittenCommunications" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="width:2.9%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.38%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:SolicitingMaterial" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="width:2.9%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.38%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:PreCommencementTenderOffer" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="width:2.9%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:5.38%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:91.72%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000018" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000899460_20220524_20220524">Common Stock, par value $0.01 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000899460_20220524_20220524">MNKD</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000899460_20220524_20220524" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;border-top:Solid 1pt #000000;padding-top:0pt;border-bottom:Solid 2.5pt #000000;padding-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01  Other Events.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 24, 2022, MannKind Corporation (the &#8220;Company&#8221;) issued a press release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated herein by reference, except the website addresses and hyperlinks contained in such press release are inactive textual references only and no information accessible through any such website address or hyperlink is incorporated by reference herein.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01&#160;&#160;Financial Statements and Exhibits.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.94%;width:99.06%;">
<tr>
<td valign="top" style="width:10.94%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p></td>
<td valign="top" style="width:2.34%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:86.72%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="mnkd-ex991_26.htm"><span style="text-decoration:underline;">Press release dated May 24, 2022</span></a></p></td>
</tr>
<tr style="height:6.7pt;">
<td valign="top" style="width:10.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:2.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="top" style="width:86.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:10.94%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 104</p></td>
<td valign="top" style="width:2.34%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:86.72%;">
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements in Exhibit 99.1 to this report that are not statements of historical fact are forward-looking statements, including statements regarding the expected timing for Tyvaso DPI product availability. These forward-looking statements are based upon the Company&#8217;s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include risks and uncertainties regarding manufacturing pharmaceutical products. These and other risks are detailed in the Company&#8217;s filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), including under the heading &#8220;Risk Factors&#8221; in MannKind&#8217;s Quarterly Report on Form&#160;10-Q&#160;for the quarter ended March&#160;31, 2022, filed with the SEC on May&#160;5, 2022. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this report.</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.17%;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.17%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MannKind Corporation</p></td>
</tr>
<tr>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 25, 2022</p></td>
<td valign="top" style="width:10%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&#160;</p></td>
<td valign="top" style="width:42%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David Thomson, Ph.D., J.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David Thomson, Ph.D., J.D.</p></td>
</tr>
<tr>
<td valign="top" style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, General Counsel and Secretary</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mnkd-ex991_26.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
mnkd-ex991_26.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 99.1</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gt0ly1um5okc000001.jpg" title="" alt="" style="width:155px;height:25px;"><font style="color:#BD1A8D;font-size:22.5pt;font-weight:normal;margin-left:306pt;"></font>FOR IMMEDIATE RELEASE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MANNKIND&#8217;S TECHNOSPHERE<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> INHALATION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PLATFORM UTILIZED IN FDA-APPROVED TYVASO DPI&#8482; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:14pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:14pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:14pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:14pt;font-family:Times New Roman;color:#000000;">Tyvaso DPI represents the second FDA-approved product utilizing MannKind&#8217;s Technosphere<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> inhalation technology</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:14pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:14pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:14pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:14pt;font-family:Times New Roman;color:#000000;">First approval of a dry powder inhaled treatment for PAH and PH-ILD</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:14pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:14pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:14pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><a name="_Hlk104189108"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;font-size:14pt;font-family:Times New Roman;color:#000000;">Manufacturing of Tyvaso DPI for United Therapeutics underway at MannKind&#8217;s Connecticut facility with product availability expected in June 2022</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 24, 2022<font style="font-weight:normal;"> (Globe Newswire) &#8211; </font>MannKind Corporation (Nasdaq: MNKD)<font style="font-weight:normal;">, a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, celebrated today that the U.S. Food and Drug Administration (FDA) has approved United Therapeutics&#8217; Tyvaso DPI&#8482; (treprostinil) inhalation powder for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso DPI represents the second FDA-approved product utilizing MannKind&#8217;s innovative Technosphere<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> inhalation technology and is the first and only approved dry powder inhaled treatment for these indications.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are elated that Tyvaso DPI has received approval from the FDA, which paves the way for patients to receive treprostinil in a new and convenient way,&#8221; said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. &#8220;This approval exemplifies MannKind&#8217;s commitment to developing products that give people control of their health and the freedom to live life. With Tyvaso DPI, patients can potentially fit in the palm of their hand a full day of dosing treprostinil from a Dreamboat<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> inhaler.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">&#8220;This approval is a result of the hard work of the research, development, regulatory, and operations teams at MannKind and United Therapeutics,&#8221; said Patrick Poisson, Executive Vice President of Technical Operations at United Therapeutics. &#8220;We are thrilled to provide a dry powder inhaled alternative to liquid nebulization of Tyvaso.&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MannKind and United Therapeutics entered into a worldwide exclusive licensing and collaboration agreement in September 2018 for the development and commercialization of Tyvaso DPI. In August 2021, the two companies established a commercial supply agreement that has an initial term through 2031. A next-generation formulation of treprostinil, Tyvaso DPI incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind&#8217;s Afrezza<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (insulin human) Inhalation Powder, which was </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved by the FDA in 2014. Tyvaso DPI is produced at MannKind&#8217;s manufacturing facility in Connecticut.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PAH is a life-threatening high blood pressure in the arteries of the lungs, affecting the ability of the heart and lungs to work properly in afflicted patients. PAH affects an estimated 45,000 patients in the United States. ILD is a group of lung diseases in which marked scarring occurs within the lungs. It is often complicated by pulmonary hypertension (PH), which furthers symptoms and decreases survival. PH is estimated to affect at least 15% of patients with early-stage ILD (approximately 30,000 PH-ILD patients in the United States) and may affect up to 86% of patients with more severe ILD. Tyvaso<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> and Tyvaso DPI are the only therapies approved by the FDA to treat PH-ILD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">About TYVASO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (treprostinil) Inhalation Solution and TYVASO DPI&#8482; (treprostinil) Inhalation Powder</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eyebrow (abbreviated) Indication</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">For the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;Background-color:#FFFFFF;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INDICATION </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prostacyclin mimetics indicated for the treatment of:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.46%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with TYVASO establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.31%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.31%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.31%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.31%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are long-term data on use of treprostinil by other routes of administration, nearly all clinical experience with inhaled treprostinil has been on a background of an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. The controlled clinical experience with TYVASO was limited to 12 weeks in duration.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.31%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.46%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><a name="_Hlk11139610"></a><a name="_Hlk11674022"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;"><a name="_Hlk11674022"></a>Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with TYVASO establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">IMPORTANT SAFETY INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WARNINGS AND PRECAUTIONS</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">TYVASO and TYVASO DPI are pulmonary and systemic vasodilators. In patients with low systemic arterial pressure, either product may produce symptomatic hypotension.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Both products inhibit platelet aggregation and increase the risk of bleeding.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both C<sub style="font-size:85%; vertical-align:bottom">max</sub> and AUC) to treprostinil. Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. Increased exposure is likely to increase adverse events associated with treprostinil administration, whereas decreased exposure is likely to reduce clinical effectiveness.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Like other inhaled prostaglandins, TYVASO and TYVASO DPI may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased risk for bronchospasm. Ensure that such patients are treated optimally for reactive airway disease prior to and during treatment with TYVASO and TYVASO DPI.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DRUG INTERACTIONS/SPECIFIC POPULATIONS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">The concomitant use of either product with diuretics, antihypertensives, or other vasodilators may increase the risk of symptomatic hypotension.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor, gemfibrozil, increases exposure (both C<sub style="font-size:85%; vertical-align:bottom">max</sub> and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer, rifampin, decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. However, pulmonary arterial hypertension is associated with an increased risk of maternal and fetal mortality. There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Safety and effectiveness in pediatric patients have not been established. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-family:Times New Roman;color:#000000;">Across clinical studies used to establish the effectiveness of TYVASO in patients with PAH and PH&#8209;ILD, 268 (47.8%) patients aged 65 years and over were enrolled. The treatment effects and safety profile observed in geriatric patients were similar to younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of hepatic, renal, or cardiac dysfunction, and of concomitant diseases or other drug therapy. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADVERSE REACTIONS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Pulmonary Arterial Hypertension (WHO Group 1)</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a 12-week, placebo-controlled study (TRIUMPH I) of 235 patients with PAH (WHO Group 1 and nearly all NYHA Functional Class III), the most common adverse reactions seen with TYVASO in &#8805;4% of PAH patients and more than 3% greater than placebo were cough (54% vs 29%), headache (41% vs 23%), throat irritation/pharyngolaryngeal pain (25% vs 14%), nausea (19% vs 11%), flushing (15% vs &lt;1%), and syncope (6% vs &lt;1%). In addition, adverse reactions occurring in &#8805;4% of patients were dizziness and diarrhea.</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a 3-week, open-label, single-sequence, safety and tolerability study (BREEZE) conducted in 51&#160;patients on stable doses of TYVASO who switched to a corresponding dose of TYVASO DPI, the most commonly reported adverse events seen with TYVASO DPI in &#8805;4% of PAH patients during the 3-week treatment phase included cough (35.3%), headache (15.7%), dyspnea (7.8%), and nausea (5.9%).</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0.96%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-family:Times New Roman;color:#000000;">Pulmonary Hypertension Associated with ILD (WHO Group 3)</font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a 16-week, placebo-controlled study (INCREASE) of 326 patients with PH-ILD (WHO Group 3), adverse reactions with TYVASO were similar to the experience in studies of PAH.</p>
<p style="Background-color:#FFFFFF;margin-bottom:9pt;margin-top:9pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please see Full Prescribing Information for <font style="color:#auto;text-decoration:underline;">TYVASO</font> or <font style="color:#auto;text-decoration:underline;">TYVASO DPI</font>, Instructions for Use manuals for <font style="color:#auto;text-decoration:underline;">TD-100 and TD-300</font> TYVASO<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> Inhalation System and <font style="color:#auto;text-decoration:underline;">TYVASO DPI<sup style="font-size:85%;line-height:120%;vertical-align:top">&#8482;</sup> Inhalation Powder</font>, and additional information at <font style="color:#auto;text-decoration:underline;">www.TYVASOHCP.com</font> or call 1&#8209;877&#8209;UNITHER (1-877-864-8437).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TYVISIhcpMAY2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk100660266"></a>About MannKind Corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of therapeutic and convenient products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza<font style="font-style:italic;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font> (insulin human) Inhalation Powder, the Company&#8217;s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company&#8217;s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S.&nbsp;&nbsp;Please visit <font style="color:#auto;text-decoration:underline;">mannkindcorp.com</font> to learn more.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AFREZZA, DREAMBOAT and TECHNOSPHERE are registered trademarks of MannKind Corporation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TYVASO is a registered trademark of United Therapeutics Corporation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TYVASO DPI is a trademark of United Therapeutics Corporation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"># # #</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">For MannKind</font>:<font style="margin-left:288pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christie Iacangelo, Corporate Communications<font style="margin-left:288pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(818) 292-3500<font style="margin-left:288pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="color:#auto;text-decoration:underline;">media@mannkindcorp.com</font><font style="margin-left:288pt;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rose Alinaya, Investor Relations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(818) 661-5000</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: <font style="color:#auto;text-decoration:underline;">ir@mannkindcorp.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gt0ly1um5okc000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gt0ly1um5okc000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, <8# 2(  A$! Q$!_\0
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MT2X2QU.62;3'(4,Q+-;]@1_L^J]NH[@S4PME>)EB<F<(N5%W\F>W5X%\1_\
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M7PGO=/TR2ZL+[[?+'\S0"#8S+WV_,<GV[]N< ^P111P1)%%&L<:*%1$& H'
M '84^O.>*J7NCY26;XEU.9/3M;^F?+%%:&NVT5GXAU*U@79##=RQQKG.%#D
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MX07L]HLE_J<5I,W/E1Q>;M&!U.X#.<CC(XZFD^$&G03ZIJ&H2#=+:QHD0(!
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M^A"J_P#[(:,3#F<1YI056=)=W;Y'E6I:A<:MJ=Q?W3;IIY"[<D@9Z 9). .
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M$$BO9]%^)F@ZG'&MW+_9]RS;3'-DI]=^,8^N*PQ-&7-S(\[-<#4]JZT%=/\
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MU[5Y]2NKF^2:;;N6)T"C"A1C*D]!ZU$)I5FSGP^(C''5)O9K_(\'KZ2\,?\
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M5H6OLTMW:>7<M_R\0'8_;D]F/&.0:*.)M[LA8'-7!*E55UT9\\T5N>+M&M]
M\13Z?:O*\,84@RD%N1[ 5H^ _"]EXHO[N"^EN(UAB#J864$G..<@UV\RM<^@
M=5*'M.A@:3I%[K>H)96$#2S-R<=%7NS'L*HU]+Z5HFF:';F'3;.*W1OO%1EF
MY)&YCR<9.,GBN0_X5%H'_/YJ?_?V/_XBL(8A2;TT/-P^:1JREIHK6_$\7HKV
9C_A46@?\_FI_]_8__B**T]M$ZOKM/LS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>mnkd-20220524.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-25T04:33:57.9102287+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cef399ca9569475da797e99c2658f7d2 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:mnkd="http://www.mannkindcorp.com/20220524" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mannkindcorp.com/20220524" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" namespace="http://xbrl.sec.gov/currency/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" namespace="http://xbrl.sec.gov/sic/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" namespace="http://fasb.org/srt-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" namespace="http://fasb.org/us-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.mannkindcorp.com/20220524/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnkd-20220524_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mnkd-20220524_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>mnkd-20220524_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-25T04:33:57.9102287+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cef399ca9569475da797e99c2658f7d2 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>mnkd-20220524_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-05-25T04:33:57.9102287+00:00 -->
<!-- Version            : 5.0.1.747 -->
<!-- Package ID         : cef399ca9569475da797e99c2658f7d2 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mannkindcorp.com/20220524/role/TemplateLink" xlink:href="mnkd-20220524.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mnkd-20220524.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140579515391224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MANNKIND CORP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000899460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 24,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3607736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Casper Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Danbury<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-5000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MNKD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>mnkd-8k_20220524_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mnkd-20220524.xsd" xlink:type="simple"/>
    <context id="C_0000899460_20220524_20220524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000899460</identifier>
        </entity>
        <period>
            <startDate>2022-05-24</startDate>
            <endDate>2022-05-24</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName contextRef="C_0000899460_20220524_20220524" id="F_000000">MANNKIND CORP</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="C_0000899460_20220524_20220524" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000899460_20220524_20220524" id="F_000002">0000899460</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000899460_20220524_20220524" id="F_000003">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000899460_20220524_20220524" id="F_000004">2022-05-24</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000899460_20220524_20220524" id="F_000005">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000899460_20220524_20220524" id="F_000006">000-50865</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000899460_20220524_20220524" id="F_000007">13-3607736</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000899460_20220524_20220524" id="F_000008">1 Casper Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000899460_20220524_20220524" id="F_000009">Danbury</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000899460_20220524_20220524" id="F_000010">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000899460_20220524_20220524" id="F_000011">06810</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000899460_20220524_20220524" id="F_000012">(818)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000899460_20220524_20220524" id="F_000013">661-5000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000899460_20220524_20220524" id="F_000014">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000899460_20220524_20220524" id="F_000015">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000899460_20220524_20220524" id="F_000016">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000899460_20220524_20220524" id="F_000017">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000899460_20220524_20220524" id="F_000018">false</dei:EntityEmergingGrowthCompany>
    <dei:Security12bTitle contextRef="C_0000899460_20220524_20220524" id="F_000019">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000899460_20220524_20220524" id="F_000020">MNKD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000899460_20220524_20220524" id="F_000021">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ QH"Y5)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    " #&@+E4L&?%K.X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #&@+E4F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( ,: N50%(IBT* 0  #00   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #&@+E4GZ ;\+$"  #B#
M#0              @ %K#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,:
MN527BKL<P    !,"   +              "  4</  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( ,: N50<.&7J/P$  #P"   /              "  3 0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #&@+E4)!Z;HJT   #X 0  &@
M            @ &<$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #&@+E499!YDAD!  #/ P  $P              @ &!$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #+$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mnkd-8k_20220524.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="mnkd-8k_20220524.htm">mnkd-8k_20220524.htm</File>
    <File>mnkd-20220524.xsd</File>
    <File>mnkd-20220524_lab.xml</File>
    <File>mnkd-20220524_pre.xml</File>
    <File>mnkd-ex991_26.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mnkd-8k_20220524.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "mnkd-8k_20220524.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mnkd-20220524_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mnkd-20220524_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mnkd-20220524.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "mnkd",
   "nsuri": "http://www.mannkindcorp.com/20220524",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "mnkd-8k_20220524.htm",
      "contextRef": "C_0000899460_20220524_20220524",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "mnkd-8k_20220524.htm",
      "contextRef": "C_0000899460_20220524_20220524",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.mannkindcorp.com/20220524/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001564590-22-021266-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-021266-xbrl.zip
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M*=)J"5D,"G&@)J]?V0XNON'U/KQL+_S#GEONU'MSL55<%U?_ %!+ P04
M" #'@+E4C^L[AO<&  #P2   %0   &UN:V0M,C R,C U,C1?;&%B+GAM;,U<
M77/B-A1][TS_@TI?=J=K#"19%F:3G30?':9LD@G9=J>=SHZP!=&LD!C))/#O
M*]DFL4$V_A"+>,$XTCE7YYYKR8KAXZ?EC( GQ 5F]+31;K8: %&/^9A.3QL+
MX4#A8=P (H#4AX11=-I8(='X=/;S3Q]_<1QP>3VX >=>@)_0)18>86+!T9O1
MY[?@Z^_W0S#$]/L8"@0NF;>8(1H !SP&P;SONL_/STU_@JE@9!%(=M'TV,P%
MCK.&ON (JC^ 2Q@@$+[ZH-/J=)S6B=,Y>6@=]X^.^B?=9J\M3W[H_M9J]5NM
M!,!?T;! XM4')\U6L]WL'G<3#>^@]QU.$1A<)AIZ:'+4ZWFP=_*^=]P]\6&W
MUT7R1.?]R8=)U^\D(V7S%<?3QP"\\=Z&(<KQ4HH(02MPC2FD'H8$C-8C?0<&
MU&N"<T+ O>HFP#T2B#\AOQFC$JE;GZS%DSFB(OQXVDBHMQQSTF1\ZG9:K2-W
MW;H1-U]NM7\^"ENW>[V>&_[UI:G NH82MNU^_3P<>8]H!AV9*ND"3Q$(W!?A
MR2'SPAP5B MDME"?G'4S1YURVAWGJ-U<"K\AU0 @TH,S@N[1!*CW+_>#3,Z>
MJUJX%$VE<?PA'",B8PXA'CF:Z/L1SE/=5!P]%4?[O8KC5QU:L)K+>A!X-B=2
M%;=VJ#<H,!OM)J#I@.\0Q\R_HH9%UL/N)_A1 +EAU;. 30_@05[?D-G0MR&-
M!\T"2 P'O05I,.@*W@BVXZQKA D4XY!&3LE3".<1%5&@+EQB<8DF<$&"[3"%
M[!S&N(6@IBD7D4"H,PI...I4&+ &,COF, HUT<<M%5;.?!!%'LT^"62T#!#U
M47S!?\%F7O:0!/*:4_;D^@A'HY$'KV.0'[Y=T0 'JPNY[N"0#"3\\D^T2O,2
M-8,QOCX9#N:TD=/930>HVJMI5!ZI)1.BSI=14;!O9+SA"8X$6_!PCBVL9?!:
MLV<1#8AY0$@$)--']S6@[?C/N9>* G)O'8 \W!%#W,+UF%P;S .'))T^X6R6
MJV9,RW:JY)KTQ0632][SL9 T7E#4#QN=JOD@!6(F_Y'@9R$R^'>-_=_A4ZY7
MF64*833%D97NT10K"AK<P!DJ5_F;?>L4?AIK;W7_2@,4S^$MD)L%MDLAVQ0G
MU<2N9^1S>=OLJUOG:P*G11V\T:F:D"D0\YY]@0<*__!>U0O-,K6P1E127L_#
MKEC2=51BL5*ODM9[4 \R\**%E.Y3+>5)#/-E]+*SIN /7T5:D5F6$+8(2DII
M:<:&+[L<:G^SK!\W.M?3,06V1X=&/$ 2A7NZ]IA5GPJV4R7K9-_T<6'%32RV
M!]1C?,YXN",\"B3?!5O(:_OJ@ODEU]X[H.HL#'.A][8R3[&"D!;$O$ 1'[X6
MRN20E134\GP10ZDR4437F*";Q6R,>+F*2?:K(_<KSMYJ05& B,,6VVM49WFJ
MV*0P*2^N":,^P.7 EW,,GN#H?X!57)L)4D?@#-"]^5GR@32A9>[>E2I66#UK
MTT+J9L1$29S[OHQ=Q&]#3%&[7#EH >IHK@'<6QG$)._6!^KA#P1NJ35KF[ST
ML$*J69D*HLM"*@GM'V+["WEXRQ_8,ZUD^F1W SJ_PNW?\(H+, X4FV5FUR1%
M9_5-M2Q,@-[FH?2WNZ0WZ/+P?N"6WW'VA*E7\K8V"\. W!N8^S=]=&,D7;^F
MM,SY68G2V5\KGJU)T1="E([;(NDP6 UW3 20_(/GY;=X] @&1$\A[K\.(CH@
M^:S:R,E-D*X&-++9F0R]_PNGH>:3(VIH',$R?D_WJ?C<2 +#O*?#653!6V)A
MK<HL2PE;%"7EQ*QG1/7D-;E[9+3D;N%VOVKR;>*8-V7( $(*:_93,E5G>:K8
MI# I+VX]H_[-<1 @>L%FLP6-=V-$4;=F=*XFJ!;,O&]C&I#F.;QW\Q/!=FID
MG>BDFM[U[#QB!'LXP'3Z62ZX.8:DJ)=U/:MINHUDWL6O'&!-<G@+YXC/\J6Q
M2VA20>-ZMKWC2-4'DO*&3\ZH9^WY[612?.&0AU!-W6Q$\W:67"!)!B(V$-(=
MWM@%TL.*B69G*DBM+!BU_D"(!>+U"T"#8T3[+=P?4 P1I]TUD9TW?65DZ&AS
MCK*JI%1Z3.SN7<T0G\IIZ0_.GH-'&<L<TI+?F\J J+.EI(7<VP;?F@U$="#F
M.WQ=%$D1*ZB;I>D@]3)1<X6/O(6\I5BU.^,'')#"VWS;_2HN.C=P]K"VCQF
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M$)=AM>PT'I(Z4V,"L^2+((:J3O&WTV\]=\A&U)H557Z_; 0'Y1JU)RK/"?.
M3HE'C[ \5+(T8KD[:?=XHWP#?J\6-YC"5%2"!G(0BI$F(()<LTIEJUS/=&(!
ME^0Z2KGFL7Z:5B65V.6,@#JRH)4EHQ[^'3%%]>IBL3]B?KM?Z(0!<)NRKF".
M!>*:I_V" B8LZM:DB.T45SZ#+Z@.K>;-[ZG2LZ$.%!?3\KUB.A(J_;,OH/<#
M6"05$^06EY6RW7 2_=T/O?'!GL=OB51CG^T7/"XCGXZ1A@R!_H\]?M_&[IC
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M(X-$PAKA)XUQ:ND;W?MD&=$:UM2ZI8*#3FR3I&+AX"\_.?72[EXQ.LAB2'=
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M<X=)91Y@%'1R7=0.VNL,O3( ZH[U)5<LS6UF4O<R'(/AA_=.2:U1:1K ES$
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MD!2[LR@;THM!=$&H<'G*+;PAZ3,B@?F@  2'PS!]-J3^P(@B,S*65,!(7!Q
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M@3"?;J5_%QJ1@3\_#5_^'U!+ P04    " #'@+E4QZC2;QL8  !AP   $0
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M[>M;IL\GU)^0*[E0?T-"?95VRWM*)/5@+/\Y%E?5RE9U;[]:V4.&TI47^&
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M9"TX:U\R,#(R,#4R-"YH=&U02P$"% ,4    " #'@+E4QZC2;QL8  !AP
M$0              @ %E(P  ;6YK9"UE>#DY,5\R-BYH=&U02P4&      4
,!0!& 0  KSL

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
